Clinical Trials & Surveys Corp. (C-TASC), a clinical trials solutions company, announced today that it has been selected to provide data management software and services to New York University School of Medicine (NYU), one of eight sites collecting data for a study being conducted by the Early Detection Research Network.
NEW YORK UNIVERSITY TAPS C-TASC FOR
CLINICAL STUDY DATA MANAGEMENT
Early Detection Research Network Study Aims to Improve
Early Diagnosis of Lung Cancer
Baltimore, Md. – (December 8, 2008)-Clinical Trials & Surveys Corp. (C-TASC), a clinical trials solutions company, announced today that it has been selected to provide data management software and services to New York University School of Medicine (NYU), one of eight sites collecting data for a study being conducted by the Early Detection Research Network. The purpose of the study is to identify biomarkers to serve as early detectors of lung cancer.
Under the three year contract, C-TASC will implement its StudyCTMSTM clinical trials management software solution to manage all EDRN study data collected and maintained at the New York University site. The software will be utilized to convert tens of thousands of existing data records into one universal format. Housing the data in a single format will make the accumulated results easier to read, compile, analyze and prepare for submission upon completion of the study. StudyCTMSTM will also be used for the collection and validation of all enrollment, follow up and specimen data for the 1,100 current study participants as well as all future participants.
C-TASC’s new Bio Repository Management System (BRMS), a fully integrated module of StudyCTMSTM, will also be deployed at NYU, enabling investigators to easily manage the processing, delivery, archival and allocation of all EDRN laboratory research specimens catalogued at the study site.
StudyCTMSTM is C-TASC’s proprietary Web-based data management solution that enables investigators to easily develop and manage clinical studies and deliver the accumulated data and metadata (labels, value labels, etc.) in an easy-to-read and FDA-acceptable format.
“C-TASC’s implementation of StudyCTMSTM at NYU is significant because it marks our first private software lease to a non-government supported researcher,” said Bruce Thompson, president of C-TASC. “Working with the EDRN will allow us to fine-tune the program’s array of features to ensure that we are providing clinical investigators with the optimum user experience to support their clinical trial work.”
About C-TASC
Based in Baltimore, Maryland, Clinical Trials & Surveys Corp. (C-TASC) is a clinical trials solutions company that supports best practices management of clinical trials, clinical cohort studies, case/control studies, clinical registries and laboratory studies. Founded in 1989, C-TASC provides clients with complete research management including medical and statistical study design, project management, performance monitoring and data quality control and analysis as well as support for study publication and presentations. C-TASC’s professional services group has a successful research history in cancer, cardiovascular disease, AIDS, pulmonary disease, Cystic Fibrosis, pharmaco-epidemiology and bio-repository establishment and coordination. For more information about C-TASC’s projects, products and services, please visit www.c-tasc.com <http://www.c-tasc.com/> .
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.